7.46

1.45% -0.11

Eupraxia Pharmaceuticals Inc (EPRX)

Overview News Price History Discussions Forecast

Eupraxia Pharmaceuticals Inc stock is traded at $7.46, with a volume of 1.05M. It is down -1.45% in the last 24 hours and down -7.67% over the past month. Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Previous Close:

$7.57

Open:

$7.57

24h Volume:

1.05M

Relative Volume:

2.16

Market Cap:

$492.91M

Revenue:

Net Income/Loss:

$-44.47M

P/E Ratio:

-7.3274

EPS:

-1.0181

Net Cash Flow:

$-33.50M

1W Performance:

+3.04%

1M Performance:

-7.67%

6M Performance:

+5.37%

1Y Performance:

+20.52%

1-Day Range:

$7.275

$7.70

1-Week Range:

$7.07

$8.07

52-Week Range:

$5.25

$9.32

Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile

Name

Eupraxia Pharmaceuticals Inc

Sector

Healthcare (1059)

Industry

Biotechnology (594)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

EPRX's Discussions on Twitter

Compare EPRX vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EPRX Eupraxia Pharmaceuticals Inc	7.46	529.25M	0	-44.47M	-33.50M	-1.0181
VRTX Vertex Pharmaceuticals Inc	510.08	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	225.00	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	746.54	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	825.03	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.76	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Initiated	William Blair	Outperform
Jul-24-25	Initiated	Cantor Fitzgerald	Overweight
Jun-26-25	Initiated	H.C. Wainwright	Buy
Jun-16-25	Initiated	Canaccord Genuity	Speculative Buy
Feb-21-25	Initiated	Craig Hallum	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy

View All

Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News

Oct 01, 2026

How Is Eupraxia Pharmaceuticals (TSX:EPRX) Using Drug Delivery Technology To Target Inflammatory Diseases? - Kalkine Media

Oct 01, 2026

Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Durable EoE Data Strengthens Investor Optimism - kalkine.ca

Oct 01, 2026

Sep 30, 2026

Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients - marketscreener.com

Sep 30, 2026

Eupraxia reports 52-week data from EoE treatment trial - Investing.com

Sep 30, 2026

Eupraxia Pharmaceuticals Posts Strong 52-Week EoE Data for EP-104GI in RESOLVE Trial - TipRanks

Sep 30, 2026

Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. - Stock Titan

Sep 30, 2026

Sep 25, 2026

Eupraxia Pharmaceuticals Stock Price Forecast. Should You Buy EPRX.TO? - StockInvest.us

Sep 25, 2026

Sep 24, 2026

Eupraxia Pharmaceuticals Price Target Announced at $17.00/Share by Wedbush - Moomoo

Sep 24, 2026

Why Eupraxia Pharmaceuticals (TSX:EPRX) Is the S&P/TSX SmallCap Biotech Investors Are Tracking - kalkine.ca

Sep 24, 2026

Eupraxia Pharmaceuticals (TSX:EPRX) Stock Slips 5.13%: RESOLVE Trial Execution, Diffusphere Formulation Pacing, and Pre-Commercial Valuation Scrutinized - kalkine.ca

Sep 24, 2026

Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating By Investing.com - Investing.com Canada

Sep 24, 2026

Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating - Investing.com India

Sep 24, 2026

Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target - Yahoo Finance

Sep 24, 2026

Sep 22, 2026

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - Eastern Progress

Sep 22, 2026

Sep 20, 2026

Eupraxia Pharmaceuticals Inc.(TSX: EPRX) added to S&P Global BMI Index - marketscreener.com

Sep 20, 2026

Sep 14, 2026

Eupraxia Pharmaceuticals at H.C. Wainwright conference: focus on durability By Investing.com - Investing.com Canada

Sep 14, 2026

WHY PMET Resources (TSX:PMET), Diversified Royalty (TSX:DIV), Eupraxia Pharmaceuticals (TSX:EPRX), Fireweed Metals (TSXV:FWZ) and Standard Lithium (TSXV:SLI) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca

Sep 14, 2026

Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Rises 5.51% as Clinical Momentum and Nasdaq Upgrade Support Investor Sentiment - kalkine.ca

Sep 14, 2026

Sep 12, 2026

Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - Kalkine

Sep 11, 2026

EPRX: Innovative annual therapy for EoE shows rapid, durable efficacy and strong commercial prospects - TradingView

Sep 11, 2026

Sep 09, 2026

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price Today: $8.07 - Gotrade

Sep 09, 2026

Sep 08, 2026